Privium Fund Management B.V. Beam Therapeutics Inc. Transaction History
Privium Fund Management B.V.
- $551 Million
- Q3 2025
A detailed history of Privium Fund Management B.V. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 61,000 shares of BEAM stock, worth $1.32 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
61,000Holding current value
$1.32 Million% of portfolio
0.27%Shares
1 transactions
Others Institutions Holding BEAM
# of Institutions
253Shares Held
98.2MCall Options Held
748KPut Options Held
619K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11MShares$240 Million1.88% of portfolio
-
Farallon Capital Management LLC San Francisco, CA10.1MShares$219 Million1.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$201 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$166 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.4.83MShares$105 Million0.07% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.53B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...